Caladrius Biosciences to Participate in Landmark’s 10th Annual Investing for Cures Virtual Forum
September 10 2020 - 8:00AM
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the
“Company”), a clinical-stage biopharmaceutical company dedicated to
the development of cellular therapies designed to reverse, not
manage, disease, announced today that management will participate
in Landmark’s 10th Annual Investing for Cures Virtual Forum being
held September 16-17, 2020.
Presentation Details:
Date & Time: Wednesday, September 16th at
2:10 p.m. (EDT)Presenter: David J. Mazzo, Ph.D.,
President and Chief Executive Officer
Landmark's 10th annual Investing for Cures (“IFC”) brings
together leaders in the intersecting worlds of Family Offices, high
net worth investors, pharma, philanthropies, foundations, and
prominent therapeutics companies to explore the changing parameters
and latest innovative technologies transforming healthcare. A
two-day virtual event, IFC will connect medical experts,
exceptional companies and investors, creating both an ongoing
dialogue and coalitions between these communities.
Based in Greenwich, CT, Landmark Angels was formed in 2008 with
a core group of 25. Now numbering approximately 300, the roster
includes accredited venture capital and private equity investors,
high net worth investors, former executives of major corporations,
successful entrepreneurs and prominent family offices, asset
management and hedge funds.
About Caladrius Biosciences
Caladrius Biosciences, Inc. is a clinical-stage
biopharmaceutical company dedicated to the development of cellular
therapies designed to reverse, not manage, disease. We are
developing first- in-class cell therapy products based on the
notion that our body contains finely tuned mechanisms for
self-repair. Our technology leverages and enables these mechanisms
in the form of specific cells, using formulations and modes of
delivery unique to each medical indication.
The Company’s current product candidates include CLBS119, a
CD34+ cell therapy product candidate for the repair of lung damage
found in patients with severe COVID-19 infection who have
experienced respiratory failure, for which the Company plans to
initiate a clinical trial in the coming weeks as well as three
developmental treatments for ischemic diseases based on its CD34+
cell therapy platform: HONEDRA® (formerly CLBS12), recipient of
SAKIGAKE designation and eligible for early conditional approval in
Japan for the treatment of critical limb ischemia (“CLI”) based on
the results of an ongoing clinical trial; CLBS16, the subject of a
recently completed positive Phase 2 clinical trial in the U.S. for
the treatment of coronary microvascular dysfunction (“CMD”); and
CLBS14, a Regenerative Medicine Advanced Therapy (“RMAT”)
designated therapy for which the Company has finalized with the
U.S. Food and Drug Administration (the “FDA”) a protocol for a
Phase 3 confirmatory trial in subjects with no-option refractory
disabling angina (“NORDA”). For more information on the company,
please visit www.caladrius.com.
Contact:
Investors: Caladrius Biosciences, Inc. John Menditto Vice
President, Investor Relations and Corporate Communications
Phone: +1-908-842-0084 Email: jmenditto@caladrius.com
Media: W2O Group Christiana Pascale Phone: +1-212-257-6722
Email: cpascale@w2ogroup.com
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Apr 2023 to Apr 2024